Radiopharm Theranostics Ltd
RAD
Company Profile
Business description
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Contact
62 Lygon Street
Suite 1, Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
14
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.20 | 8.30 | -0.09% |
| CAC 40 | 8,089.26 | 173.90 | 2.20% |
| DAX 40 | 24,035.07 | 625.70 | 2.67% |
| Dow JONES (US) | 47,998.68 | 257.88 | 0.54% |
| FTSE 100 | 10,433.15 | 183.63 | 1.79% |
| HKSE | 25,959.90 | 551.44 | 2.17% |
| NASDAQ | 22,843.75 | 147.81 | 0.65% |
| Nikkei 225 | 54,248.39 | 1,519.67 | 2.88% |
| NZX 50 Index | 13,094.37 | 4.46 | -0.03% |
| S&P 500 | 6,824.06 | 28.07 | 0.41% |
| S&P/ASX 200 | 8,692.60 | 11.80 | -0.14% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |